ID   LMS6-93
AC   CVCL_WV02
DR   IARC_TP53; 10309
DR   Wikidata; Q95982648
RX   PubMed=9664117;
RX   PubMed=10737722;
CC   Doubling time: 20.3 +- 5.1 hours (PubMed=9664117).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.His214fs (c.642_643insG); Zygosity=Heterozygous (PubMed=9664117).
CC   Derived from site: In situ; Lung, smooth muscle; UBERON=UBERON_0004225.
DI   NCIt; C5667; Lung leiomyosarcoma
DI   ORDO; Orphanet_64720; Leiomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 19-12-24; Version: 7
//
RX   PubMed=9664117; DOI=10.3892/ijo.13.2.241;
RA   Meye A., Bache M., Hinze R., Schmidt H., Wurl P., Holzhausen H.-J.,
RA   Rath F.-W., Taubert H.;
RT   "Molecular characterization and liposomal transfection of a
RT   p53-mutated cell line established from a poorly differentiated
RT   leiomyosarcoma.";
RL   Int. J. Oncol. 13:241-248(1998).
//
RX   PubMed=10737722; DOI=10.1016/S0304-3835(99)00356-0;
RA   Meye A., Wurl P., Bache M., Bartel F., Grunbaum U., Mansa-ard J.,
RA   Schmidt H., Taubert H.;
RT   "Colony formation of soft tissue sarcoma cells is inhibited by
RT   lipid-mediated antisense oligodeoxynucleotides targeting the human
RT   mdm2 oncogene.";
RL   Cancer Lett. 149:181-188(2000).
//